Immunoaffinityutilizes the presence of distinct protein biomarkers such as EpCAM(epithelial cell adhesion molecule) on the surface of target cancercells to capture them onto a desired location.4 The CellSearch system is the only Food and Drug Administration (FDA)approved positive enrichment immunoaffinity technology so far forsome cancer types, such as breast, prostate, and colorectal cancer,and separates the CTCs magnetically using the functionalized ferrofluidnanoparticles with EpCAM antibody. This evidence concerns the gene EPCAM and colorectal cancer.